Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
暂无分享,去创建一个
M. Gnant | Z. Bago-Horvath | P. Dubsky | C. Wiltschke | G. Steger | R. Mader | R. Bartsch | C. Zielinski | M. Rudas | U. Pluschnig | S. Gampenrieder | A. Rottenfusser | C. De Vries